Related: South Valley University in Egypt’s Clinical Trial Reveals Ivermectin-based Nasal Spray Improves COVID-19 Outcomes. It has an increasing list of indications due to its antiviral and anti-inflammatory properties, and is included on the WHO’s Model List of Essential Medicines. It’s been used for decades for this purpose by over 3.7 billion people, and is considered safe and effective. Ivermectin is an anti-parasitic medication widely used in low- and middle-income countries to treat parasitic worm infections in adults and children. The cooperation partners plan to publish the data in a peer reviewed journal.Ĭheck out the summary of evidence on Iota-Carrageenan versus COVID-19 from (constantly updated). Taken together, the data show how Carragelose can effectively inhibit SARS-CoV-2 variants in tissue culture. Both are established and scientifically widely accepted models. The infectious virus particles used in the cooperation with the virological institute of the University Hospital Erlangen mimic the effect of an actual infection, where the virus replicates in the host cells and then reinfects further cells, thereby spreading the infection in the body. Marinomed’s lentivirus data show the ability of Carragelose to prevent the virus from attaching to the host cell. With the data we have already seen against SARS-CoV-2 wild type, we are confident that this will hold true also for SARS-CoV-2 variants in the clinic.” With the extensive discussions we are seeing around maintaining efficacy against a mutating virus, it is reassuring to know that Carragelose is a simple, safe, and effective means of supporting the prevention and treatment of COVID-19. Prieschl-Grassauer continued: “We are very pleased to show that Carragelose is effective regardless of the actual SARS-CoV-2 variant.
Carragelose showed similar effectiveness against the SARS-CoV-2 wild type and the tested variants.ĭr. In addition, two of the three SARS-CoV-2 variants (B1.1.7 and B1.351) were independently tested in Vero cell tissue culture in cooperation with the virological institute of the University Hospital Erlangen, Germany. The non-sulfated polymers HPMC and CMC were ineffective even at the highest concentrations tested. This is clinically relevant for the use of Carragelose-containing products: The marketed nasal sprays have a Carragelose concentration of 1.2 mg / ml, a more than 200-fold higher dose as shown to be effective in vitro. Carragelose was able to inactivate all four virus forms at concentrations below 5 µg/ml. In recent in vitro tests, Marinomed included four lentiviruses differently pseudotyped with the spike protein of wild-type SARS-CoV-2 or one of the three variants B.1.1.7, B1.351 and P1, respectively. We believe that this will hold true for any future variants.” With these new results we confirmed the hypothesis that our Carragelose-based products continue to be effective also against the mutations of concern currently emerging strongly. “Given the broad antiviral efficacy and the physical mode of action, we were convinced that SARS‑CoV‑2 variants are unlikely to evade the antiviral efficacy of Carragelose. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. We are very confident in these results that show Carragelose inactivates SARS-CoV-2, independent of the mutations we tested,” said Dr. “The COVID-19 pandemic continues to be a major health, social, and economic burden, and we now see variants of SARS-CoV-2 taking over the dynamics of the pandemic. The data demonstrate that also with increasing prevalence of virus variants, the marketed OTC Carragelose-based lozenges, nasal and throat sprays will continue to effectively contribute to combatting the COVID-19 pandemic. The Company tested the three variants that currently mostly drive the COVID-19 pandemic, namely the so-called British or B.1.1.7, the South-African or B.1.351, and the Brazilian or P1 variant. Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced that Carragelose inactivates the new, rapidly spreading variants and SARS-CoV-2 wildtype with similar efficacy in vitro. Iota-CarrageenanĬarragelose is a brand name of iota-carrageenan from Marinomed. In this article, we would like to cover 2 popular treatments i.e. There is no early treatment for COVID-19? Most of the studies are small and are of low quality? We shall wait for bigger and better quality evidence before we can make formal recommendations? Before you continue to read this rather long article, let's start with the end in mind and begin with the conclusion that you may have been told.
Iota carrageenan nasal spray professional#
If you are confused about the recommendations made by different professional groups for the COVID-19 pandemic, you've come to the right place.
0 kommentar(er)
